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Abstract
The incidence of opportunistic fungal infections has increased in recent decades due to the growing proportion of
immunocompromised patients in our society. Candida krusei has been described as a causative agent of disseminated
fungal infections in susceptible patients. Although its prevalence remains low among yeast infections (2–5%), its intrinsic
resistance to fluconazole makes this yeast important from epidemiologic aspects. Non mammalian organisms are feasible
models to study fungal virulence and drug efficacy. In this work we have used the lepidopteran Galleria mellonella and the
nematode Caenorhabditis elegans as models to assess antifungal efficacy during infection by C. krusei. This yeast killed G.
mellonella at 25, 30 and 37uC and reduced haemocytic density. Infected larvae melanized in a dose-dependent manner.
Fluconazole did not protect against C. krusei infection, in contrast to amphotericin B, voriconazole or caspofungin. However,
the doses of these antifungals required to obtain larvae protection were always higher during C. krusei infection than during
C. albicans infection. Similar results were found in the model host C. elegans. Our work demonstrates that non mammalian
models are useful tools to investigate in vivo antifungal efficacy and virulence of C. krusei.
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Introduction
Fungal infections have emerged worldwide due to a growing
population of immunosuppressed patients, including patients with
cancer, AIDS, solid-organ and hematopoietic stem cell transplant
recipients, premature neonates, and patients recovering from
major surgery [1–5]. These infections have significant morbidity
and mortality rates and are difficult to prevent, diagnose and treat
[6–8].
Candida spp are commensal yeasts responsible for different
clinical manifestations, from mucocutaneous overgrowth to blood
stream infections [1,9–12]. Candida albicans is still the major cause
of invasive fungal disease. However, a growing number of
infections produced by non-albicans Candida spp has been reported
in the last years [1,13–15]. Among them, there are some species
that are intrinsically resistant or have reduced susceptibility to
antifungals. The massive use of antifungals in prophylaxis, such as
fluconazole, has facilitated the selection of pathogenic fungi
resistant to these agents [16–19].
Candida krusei is an opportunistic pathogen which presents
intrinsic resistance to fluconazole. The infection is associated with
the prophylactic or therapeutic use of this antifungal agent [20–
23]. Two mechanisms of azole resistance in C. krusei have been
described: overexpression of drug efflux pumps [24] and
diminished sensitivity of the target enzyme, the cytochrome
P450 sterol 14-demethylase (encoded by the CYP51 gene) [25].
Diseases caused by C. krusei have high associated mortality (30–
60%) [26,27]. Despite the intrinsic resistance to fluconazole, C.
krusei is usually susceptible to voriconazole in vitro, which correlates
with the binding of this drug to the target enzyme [21].
Antifungal resistance in vitro does not always correlate with
clinical resistance. The best correlation between in vitro and clinical
efficacy is found in HIV-positive patients with oropharyngeal
candidiasis [22,28,29]. In contrast, although C. parapsilosis shows
reduced in vitro susceptibility to echinocandins, these antifungals
have been shown to be effective in the treatment of invasive
candidiasis caused by this species [30].
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The use of invertebrate hosts has recently emerged and
facilitated the study of fungal pathogenesis. Among these non-
mammalian hosts, amoebae (Acanthamoeba castellanii, Dictyostellium
discoideum), nematodes (Caenorhabditis elegans) and insects (Drosophila
melanogaster, Galleria mellonella) have been successfully used to study
the virulence of some fungi [31–35]. Moreover, some aspects of
the innate response are conserved between these hosts and
mammals [36]. Galleria mellonella is a lepidopteran (Pyralidae) that
provides important advantages as host model. The larvae can be
incubated in a range of temperature between 25 to 37uC, so it is
possible to simulate the natural fungal habitat and the infection
conditions in mammals. In addition, as in mammalian models, it is
possible to introduce by injection exact doses of pathogens to the
larvae, which poses a technical improvement over other non-
conventional hosts. Galleria mellonella has six types of phagocytic
cells that play an important role in the defense system [37,38]. The
density of these cells in the haemolymph is not constant, and
changes during infection can be easily measured and used as a
parameter of the response of the larvae after exposure to
pathogens [39]. The viability of the larvae can be easily recorded
by the lack of movement and the massive melanization induced by
G. mellonella in response to infection [40–42]. Another organism
that is used as model host is the soil nematode Caenorhabditis elegans,
which feeds on microorganisms, but is susceptible to bacterial and
fungal pathogens [33,43–45]. Caenorhabditis elegans has been used to
study virulence, filamentation and antifungal efficacy of antifungal
drugs [44,46].
In this study, we initially aimed to characterize the interaction
between G. mellonella and C. krusei with two purposes: 1) To get
insights about virulence traits of this pathogenic yeast, and 2) to
investigate if antifungal efficacy in vivo correlates with the
susceptibility profile shown by C. krusei in vitro. Furthermore, we
have complemented our studies with C. elegans, and observed
similar behaviors, indicating that non-conventional models can be
used to investigate C. krusei virulence and antifungal efficacy.
Materials and Methods
Strains and media
Candida albicans SC5314 [47], C. krusei ATCC 6258 and two
clinical isolates (CL8053 and CL80317) from the Yeast Collection
of the Mycology Reference Laboratory of the Spanish National
Centre for Microbiology and Cryptococcus neoformans variety grubii
(H99 strain, ATCC 20882) were used in this study. The yeasts
were grown overnight in liquid Sabouraud medium (Difco, BD,
USA) at 30uC with shaking. Escherichia coli OP50 strain was
obtained from the Caenorhabditis Genetics Center (University of
Minnesota) and was maintained on LB agar plates at 37uC.
Antifungal susceptibility testing (AFST)
Minimum inhibitory concentration (MIC) values were deter-
mined using the EUCAST protocol [48,49]. For AFST, 10
different clinical isolates of C. albicans and 10 clinical isolates of C.
krusei were obtained from the yeast collection of the Mycology
Reference Laboratory of the Spanish National Centre for
Microbiology. Data were expressed as geometric mean, mode,
range (minimum-maximum) and MIC frequency distribution.
Insect larvae manipulation and incubation conditions
Galleria mellonella larvae (0.3–0.5 g, R.J. Mous Livebait, The
Netherlands) were placed in Petri dishes and incubated at 37uC in
the dark the night before the experiments. Larvae with color
alterations (i.e. dark spots or with apparent melanization) were
excluded. Antifungals and yeast suspensions were injected in the
haemocele through the last left pro-leg of the larvae using a 10 mL
Hamilton syringe (Hamiltion, USA). The pro-leg had been
previously cleaned with 70% ethanol. A total of 10 mL were
injected in each larva. Larvae death was monitored by visual
inspection of the color (brown-dark brown) and by lack of
movement after touching them with forceps. For each condition, a
total of 20 larvae were used, and each experiment was repeated at
least twice. After infection, larvae were incubated at 25, 30 or
37uC.
Survival assay
Yeasts were grown overnight in liquid Sabouraud, washed with
PBS, and suspended in the same buffer. Cell density was estimated
with an Automatic Cell Counter TC10 (Bio Rad). For survival
assays, larvae were inoculated with 107, 56106 and 2.56106 cells/
larva of C. krusei and 106, 56105 and 105 cells/larva of C. albicans.
The inocula were prepared in PBS plus 20 mg/L of ampicillin to
prevent bacterial contamination. The infected larvae were
incubated at 25uC, 30 or 37uC, and the death was daily monitored
during 7 days.
Growth curve at different temperatures
Yeast strains were grown overnight and diluted in fresh
Sabouraud liquid medium at 103 cells/mL. Two hundred
microliters of this suspension were placed in 96-well microdilution
plates, and incubated at 25, 30 or 37uC in a Labsystems IEMS
Reader MF spectrophotometer. Optical density (OD) was
determined at 530 nm every hour during 72 hrs.
In vivo phagocytosis assay
Yeast cells were stained with 10 mg/mL Calcofluor white
(Sigma, St. Louis, MO) for 30 min at 37uC. Then, these cells were
injected into G. mellonella larvae (107 cells/larva, 5 per group), and
phagocytosis was analyzed after 3 hrs of incubation at 25 and
37uC. Haemolymph was collected in 1.5 mL tubes and diluted 1:1
in IPS buffer (Insect Physiological Saline: 150 mM sodium
chloride, 5 mM potassium chloride, 10 mM Tris-HCl pH 6.9,
10 mM EDTA and 30 mM sodium citrate) to avoid coagulation
and melanization of the haemolymph. Haemocytes were placed
on a slide and phagocytosis was visually quantified using a Leica
DMI 3000B microscope. One hundred haemocytes from each
larva were counted in each case, and the percentage of haemocytes
containing yeasts was calculated and plotted. Cryptococcus neoformans
H99 strain was used as control. Phagocytosis was also analyzed in
larvae infected in the same way, but treated with 64 mg/kg
fluconazole or 4 mg/kg amphotericin B.
Determination of haemocyte density
Groups of five G. mellonella were infected with 107 yeast cells/
larvae and incubated at 37uC for 3 hrs. The haemolymph of each
larva was collected in 1.5 mL tubes and diluted 1:10 in IPS buffer.
The cells were counted using a haemocytometer.
Measurement of in vivo filament formation
Galleria mellonella was infected with 107 cells/larva of C. albicans
and C. krusei strains. The larvae were incubated at 37uC for
24 hours. Larvae were macerated in 100 mm nylon cell strainers
(Falcon, BD, USA) with 1 mL of IPS. The liquid was then
collected, centrifuged and suspended in 1 mL of the same buffer.
Samples were stained with Calcofluor white (Sigma, St. Louis,
MO), as described above, and yeast morphology was observed
with a Leica DMI 3000B fluorescence microscope.
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Melanization quantification
Larvae were infected with PBS, 56105, 106 and 56106 cells/
larva of C. krusei. Then, the haemolymph of each larva was
collected after 3 and 24 hrs in 1.5 mL tubes and diluted 1:10 with
IPS buffer. The samples were placed in 96 well microdilution
plates. To quantify melanin levels, we took advantage of existing
protocols that quantify laccase activity by detecting the final
product of the reaction by measuring the OD in the visible range
(400–500) [50,51]. In our conditions, we observed that 405 nm
was an optimal OD to quantify larval melanin and to correlate the
results with the visualization of the dark compound. So the OD at
405 nm was measured using a Labsystems IEMS Reader MF
spectophotometer. Melanization of larvae infected with C. albicans
(56105 cells/larva) and C. krusei (56106 cells/larva) and treated
with 64 mg/kg fluconazole and 4 mg/kg amphotericin B was also
evaluated.
Treatment with antifungal drugs
Infected larvae were treated with amphotericin B (1, 2 or 4 mg/
kg, Sigma Aldrich Quimica, Madrid, Spain), fluconazole (128, 64,
32, 12, or 4 mg/kg, Pfizer SA, Madrid, spain), voriconazole (7.5 or
10 mg/kg, Pfizer SA, Madrid, Spain) or caspofungin (1, 2 or
4 mg/kg Merck & Com, Inc, NJ, USA). In some experiments, a
combination of fluconazole and amphotericin B was also used.
Antifungals were applied immediately after the infection. Groups
of 10 larvae were treated with the antifungals alone to test the
toxicity.
Fungal burden determination
Infected larvae were selected at different times of infection,
washed with 70% ethanol and cut into small pieces with a scalpel.
Two mL of PBS-ampicillin were added and the mix was
homogenized gently with a vortex and glass beads for 10 seconds.
The mix was finally suspended in 9 mL of PBS-ampicillin.
Different dilutions were made for each sample and 50 mL from
these dilutions were placed on Sabouraud-cloramphenicol agar
plates (Oxoid). The plates were incubated at 37uC for 48 h, and
the number of colony forming units (CFUs) was determined.
Histology
Three larvae from different groups (uninfected, infected and/or
treated with antifungals) were collected on different days of the
infection. The larvae were preserved in 70% ethanol and
longitudinal incisions were made with a scalpel in the dorsal part.
The samples were fixed with 10% buffered formaline for 24 hrs.
Then, the samples were dehydrated with increasing concentrations
of ethanol, rinsed with xylol, and embedded in paraffin. Tissue
sections (5 microns) were stained with periodic acid Schiff (PAS)
solution and observed with a Leica DMI3000 microscope.
Caenorhabditis elegans strain and infection conditions
The following C. elegans mutant strain, obtained from CGC, was
used in all experiments: AU37 (glp-4(bn2) I; sek-1(km4) X). This
strain was grown on agar plates seeded with E. coli OP50 and
incubated at 15uC according to standard procedures [52]. This
strain is usually chosen for virulence and antifungal efficacy assays
because glp-4 mutants are sterile at 25uC. This allows to easily
following up the survival of the individual animals from the
beginning to the end of the experiment and avoids mixing with
their progeny [33,44]. The sek-1 gene encodes a mitogen-activated
protein kinase which is important for the defense of C. elegans
against microbial infections [33,44]. Therefore worms defective for
sek-1 are more susceptible to infection and die earlier than wild-
type C. elegans animals. Candida strains were cultivated in liquid
Sabouraud medium (Difco, BD, USA) at 35uC with shaking. One
hundred mL from this culture were inoculated on solid BHI media
(Difco) containing kanamycin (90 mg/mL) and ampicillin (200 mg/
mL) and incubated at 30uC for 24 hours. Synchronized worms in
the L4 stage were added to the center of the agar plates inoculated
with the yeast strains lawns and incubated for three hours at 25uC.
In parallel, L4 worms were placed on agar plates containing lawns
of E. coli OP50 strain. After the three hours incubation, worms
were washed with M9 and transferred to 12-well plates with 1 mL
60% M9 buffer [45], 40% BHI, 10 mg/mL cholesterol in ethanol,
200 mg/mL ampicilin and 90 mg/mL kanamycin. Around 20–30
worms were placed in each well. For antifungal efficacy,
amphotericin B (1 and 2 mg/mL), fluconazole (12 mg/mL),
voriconazole (0.25, 7.5 and 10 mg/mL), caspofungin (2, 4 and
6 mg/mL), or a combination of amphotericin B (1 mg/mL) plus
fluconazole (12 mg/mL) were added to the media. Plates were
incubated at 25uC and individual worm survival was monitored
daily. Nematodes were considered dead when they did not
respond to touching. A minimum of two independent experiments
was carried out for each treatment. Images were captured with a
video camera (JVC KY-F550) attached to a dissecting microscope
(Leica MZ7.5).
Statistics
Graphs and Statistics analyzes were performed with Graph Pad
Prisma 5 (La Jolla CA, USA). Survival curves were analyzed by
Log-rank (Mantel-Cox) Test and phagocytosis assays, haemocyte
density, melanization quantification and fungal burden were
analyzed using t-Test.
Results
Candida krusei killed G. mellonella in a dose dependant
manner
We first investigated if C. krusei killed G. mellonella. Our results
showed that G. mellonella is susceptible to C. krusei infection
(Figure 1A). The death rate of the larvae depended on the yeast
dose injected. Most reproducible results were found when larvae
were infected with 56106 C. krusei cells. However, C. krusei was less
virulent than other fungi, such as C. albicans, which killed G.
mellonella at lower doses (56105, Figure 1B). To confirm that the
death was not a consequence of a shock due to big amounts of
yeast injected in the larvae, we inoculated a group of larvae with
yeast inactivated by incubation in 4% paraformaldehyde. As
shown in Figure 1C, inactivated yeast did not kill G. mellonella,
confirming that larvae death was dependent on living yeast.
To verify if C. krusei virulence in G. mellonella depended on the
temperature at which the larvae are incubated, we compared
virulence of C. krusei and C. albicans at different temperatures (25,
30 or 37uC). Candida albicans was more virulent at 37uC than at
30uC. In contrast, no statistical difference was observed in the
survival of G. mellonella infected with C. krusei and incubated at the
different temperatures, indicating that C. krusei virulence does not
depend on temperature (Figure 1D). Similar findings were
obtained with C. krusei clinical isolates (result not shown). We also
studied the virulence of these two species at environmental
temperature (25uC). In agreement with the previous data, we
found that C. krusei was virulent at 25uC, while C. albicans virulence
was significantly decreased at this temperature (data not shown).
To confirm these results, we investigated if C. krusei growth was
affected by temperature in a similar manner as C. albicans. So we
performed growth curves of both species at 30 and 37uC. As
shown in Figure 1E and F, C. albicans grew better at 37uC
Candida krusei Infection in Non-Mammalian Models
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compared to 30uC (two-fold reduction in generation time). In
contrast, C. krusei grew similarly at both temperatures (0.85 fold
decrease in generation time when the cells were grown at 37uC
compared to 30uC). We found similar results at 25uC (data not
shown), supporting that C. krusei growth is not affected by the
incubation temperature. The final OD reached at the stationary
phase at different temperatures was different with both species.
Candida albicans reached higher OD at 37uC, which differed from
the situation found in C. krusei, where the final OD at the
stationary phase was almost identical at 30 and 37uC. Latency
period was longer at 30uC, but the same trend was observed in
both species (Figures 1E and 1F).
Yeast inoculation caused early melanization of the larvae
Galleria mellonella larvae appeared melanized after a few minutes
of C. krusei injection (Figure 2A). To quantify this phenomenon, we
collected the haemolymph and measured its optical density at
405 nm. When larvae were infected with 56106 C. krusei cells,
there was a significant accumulation of melanin in the haemo-
lymph (4.3 times compared to the non-infected larvae), and this
melanization increased over time (5 times at 24 hrs, Figure 2B).
Clinical isolates showed a similar behavior (Figures 2C and D). We
evaluated if C. krusei induced melanization of G. mellonella at lower
temperatures, and we found that this phenomenon also occurred
at 25uC (data not shown).
Phagocytosis and effect of C. krusei on haemocyte
density
We examined if different C. krusei strains had any effect on
haemocyte density. As shown in Figure 3A, C. krusei produced a
decrease in haemocyte density in a similar manner to C. albicans.
We then investigated if C. krusei cells were phagocytosed by G.
mellonella haemocytes. We compared the phagocytosis of this
pathogen to the one measured with C. albicans and C. neoformans.
The phagocytosis for all Candida strains (albicans and krusei) was
significantly lower to the phagocytosis observed with C. neoformans
(Figure 3B). The same result was found when phagocytosis was
assessed at 25uC (data not shown).
Candida krusei can filament in vitro, so we investigated if this
change also took place during infection in G. mellonella. We
included C. albicans in these experiments as control, since it has
been reported that this yeast can form hyphae in this model host
[53]. As expected, C. albicans efficiently produced filaments in the
larvae. Candida krusei also produced filaments, and in G. mellonella
crude extracts they were frequently found in clumps of fat body of
dark color, which we believe that are composed mainly of insect
melanin. This fact may explain the fast melanization of G. mellonella
when infected with C. krusei.
Antifungal efficacy during C. krusei infection in G.
mellonella
One of the main features for C. krusei is its in vitro susceptibility
profile. As shown in Figure 4, C. krusei is less susceptible to
amphotericin B, voriconazole and caspofungin than C. albicans,
and intrinsically resistant to fluconazole. So we studied if this
phenotype correlated with a lack of response to the antifungal
during infection in G. mellonella. For this purpose, we infected G.
mellonella with C. krusei or C. albicans, and treated the larvae with
different antifungals (fluconazole, voriconazole, amphotericin B
and caspofungin). In the case of larvae infected with C. krusei,
treatment with fluconazole, even at very high doses (32 or 64 mg/
kg) did not increase the survival (Figures 5A and B). At higher
Figure 1. Comparison of the virulence of C. krusei and C. albicans in G. mellonella. (A) Survival curve of G. mellonella infected with different
inocula of C. krusei ATCC 6258N PBS; & 107 cells/larva; m 56106 cells/larva;. 2.56106 cells/larva incubated at 37uC (B). Survival curve of G. mellonella
infected with different inocula of C. albicans SC5314 N PBS; & 106 cells/larva; m 56105 cells/larva; .105 cells/larvae (C) Survival of G. mellonella
infected with inactivated yeast. Control dead cells N PBS; & C. krusei ATCC 6258 56106 cells/larva; m C. krusei ATCC 6258 56106 cells/larva (dead); .
C. albicans SC5314 106 cells/larva; ¤ C. albicans SC5314 106 cells/larva (dead) (D); Effect of the incubation temperature on the virulence of C. albicans
and C. krusei. N PBS; m C. krusei ATCC 6258 (37uC); .C. krusei ATCC 6258 (30uC); ¤ C. albicans SC5314 (37uC); &C. albicans SC5314 (30uC); Growth
curves of C. albicans (E) and C. krusei (F) at different temperatures. # 37uC; m 30uC.
doi:10.1371/journal.pone.0060047.g001
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concentrations (128 mg/kg), there was a decrease in the survival,
which is explained by the toxicity of the antifungal at this high
concentration, which induced 25% of death after 7 days of
treatment (data not shown). When the same experiments were
performed with C. albicans, treatment with all the fluconazole
concentrations produced significant survival (Figures 5C and 5D).
Concerning other azoles, C. krusei is considered susceptible to
voriconazole, although it presents higher MIC values to this
antifungal than C. albicans (see Figure 4). So we studied the efficacy
of voriconazole during infection in G. mellonella. We found that
both voriconazole concentrations tested (7.5 and 10 mg/kg)
protected larvae from C. albicans infection (Figure 6A). In contrast,
larvae infected with C. krusei were only protected with higher
Figure 2. Melanization of G. mellonella infected with C. krusei. (A) Visual appearance of G. mellonella larvae infected with different C. krusei
doses. (B, C and D) Optical Density (OD) of the haemolymph of G. mellonella infected with C. krusei ATCC 6258 (B), clinical isolate CL8053 (C) and
CL80317 (D) with 56105, 106, 56106 cells/larva. The different size inoculum reveals dose-response melanization (* p,0.05). All the experiments in this
figure were performed at 37uC.
doi:10.1371/journal.pone.0060047.g002
Figure 3. Interaction between C. krusei and haemocytes. (A) Changes in haemocyte density during C. krusei infection. The haemolymph of
infected larvae with C. neoformans, C. albicans SC5314, C. krusei ATCC 6258, CL8053 and CL80317 clinical isolates and PBS was collected and the
concentration of haemocytes was estimated using a haemocytometer (B). Phagocytosis percentage of C. neoformans, C. albicans SC5314, C. krusei
ATCC 6258, CL8053 and CL80317 clinical isolates. Asterisks denote differences statistically significant (p,0.05).
doi:10.1371/journal.pone.0060047.g003
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voriconazole concentrations (Figure 6B). Lower doses did not have
any effect on survival.
Amphotericin B (4 mg/kg) prolonged survival of larvae infected
with C. albicans at all the concentrations tested (Figure 6A). In
contrast, amphotericin B only protected larvae infected with C.
krusei at the highest dose (4 mg/kg), which produced a 60%
survival at the fourth day (Figure 6B). In a similar way,
caspofungin was effective during C. albicans infection at all the
doses tested (Figure 6C), while it only protected larvae inoculated
with C. krusei at the highest dose (4 mg/kg) (Figure 6D). We also
used an antifungal combination with fluconazole (12 or 4 mg/kg)
and amphotericin B at a sub-therapeutic dose in G. mellonella
(1 mg/kg), but we found no synergic effect between the antifungals
(data not shown).
Fungal burden determination and histopathology
The fungal burden was determined by recovering the yeast cells
from the larvae infected with C. albicans or C. krusei and treated
with fluconazole (12 mg/kg) or amphotericin B (4 mg/kg). The
number of CFUs increased in larvae infected with both pathogens
with the time of infection (Figure 7). Treatment of larvae infected
with C. albicans with fluconazole or amphotericin B decreased the
number of CFUs by 1000-fold (Figure 7A). In larvae infected with
C. krusei, amphotericin B reduced the fungal burden by 10-fold.
Curiously, fluconazole also reduced the initial fungal burden,
although it did not have an effect after longer times (5 days,
Figure 7B).
To complement these studies, we performed histopathology of
infected and treated larvae. Candida albicans (Figure 8C and 8D)
and C. krusei (Figure 8K and 8L) were found both in yeast and
filament forms. The antifungal treatment with fluconazole
(12 mg/kg) in larvae infected with C. albicans or C. krusei decreased
the number of yeasts. Moreover, the fungi were mainly found in
defined structures surrounded by G. mellonella cells (Figure 8E, F,
M, N). Amphotericin B (4 mg/kg) had the same effect as
fluconazole, although fewer yeast cells were found with this
treatment (Figure 8G, H, O, P). The antifungals did not have a
different effect on larvae infected with C. albicans or C. krusei.
Figure 4. Antifungal susceptibility profile of C. krusei and C. albicans. A) Distribution of MIC values (n = 10) to amphotericin B, caspofungin,
fluconazole and voriconazole of C. albicans (white bars) and C. krusei (black bars). B) Description of antifungal susceptibility of C. albicans and C. krusei
to different antifungals. N = 10. The geometric mean (GM), mode, minimum (Min) and maximum (Max) are shown.
doi:10.1371/journal.pone.0060047.g004
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Treatment with the antifungals alone did not have any effect on
the histopathology of the larvae (result not shown).
Effects of amphotericin B and fluconazole on the
physiology of G. mellonella during C. albicans and C.
krusei infection
Antifungals have immunomodulatory properties in mammals
and in G. mellonella [54–56]. We studied the effect of Amphotericin
B (4 mg/kg) and fluconazole (12 and 64 mg/kg) on haemocyte
density, melanization and phagocytosis during G. mellonella
infection by C. krusei and C. albicans. None of the antifungal
treatments influenced the haemocyte density of C. krusei infected
larvae. However, fluconazole (64 mg/kg) reduced the haemocyte
density in larvae infected with C. albicans by two fold (p = 0.017,
Figure 9A).
None of the antifungals had a significant effect on the
melanization of larvae infected with C. krusei. In contrast,
antifungal treatment of larvae infected with C. albicans reduced
melanization after 24 hours of infection. Fluconazole (64 mg/kg)
and amphotericin B (4 mg/kg) reduced the melanization of these
larvae by 1.8 (p = 0.0139) and 1.5 fold, respectively (p = 0.003,
Figure 9B). No differences were observed in melanization or
phagocytosis after 3 hours of infection with C. albicans or C. krusei.
Antifungal drugs alone did not cause any effect in G. mellonella on
the parameters analyzed.
Virulence and antifungal efficacy in C. elegans model
The nematode C. elegans is another non mammalian model that
has been used as a host to study microbial virulence in this study.
We also used this model to evaluate the in vivo protection of
antifungals during C. krusei infection such as amphotericin B,
fluconazole, voriconazole, caspofungin, and a combination of
amphotericin B plus fluconazole. Candida albicans and C. krusei both
killed C. elegans worms. In both Candida strains, worm death was
associated with filamentation of the yeast in the worms
(Figure 10A). When we investigated the protection of the different
antifungal treatments, we found that all the antifungals protected
during C. albicans infection at all the concentrations tested
(Figure 10B). In contrast, in nematodes infected with C. krusei,
the behavior of the antifungals was different: amphotericin B only
protected at concentrations $2 mg/mL and fluconazole was not
protective at any of the concentrations used (Figure 10C).
Caspofungin showed similar protection as the one observed when
the worms were infected with C. albicans (Figure 10C). The
antifungal combination of fluconazole (12 mg/mL) and ampho-
tericin B (1 mg/mL) did not show any synergistic effect in this
model (result not shown). We also studied how voriconazole
protected the worms from infection. As shown in Figure 10D, all
the concentrations used (0.25, 7.5 and 10 mg/L) protected larvae
from infection by C. albicans. However, only the higher doses (7.5
and 10 mg/L) showed efficacy during C. krusei infection, while the
lowest dose (0.25 mg/L) was not protective.
Discussion
The use of invertebrate hosts to study the virulence of microbial
pathogens presents advantages over conventional mammals.
Amoebae, nematodes and insect hosts are good models to study
virulence and to elucidate host–pathogen interaction. Ethical
issues, cost and faster results are other benefits of these models
[41,42,57]. During evolution, non vertebrate animals have
developed immunity against microbial pathogens [42], and for
this reason, there are functional and structural similarities between
the innate immune system of mammals and insects. So, these
models can be used to study immune responses [57].
In this work, we have used two different hosts, G. mellonella and
C. elegans, to investigate virulence of C. krusei and antifungal
efficacy. Compared to other non-conventional models, G. mellonella
allows the use of precise pathogen doses by injection, low cost and
Figure 5. Efficacy of fluconazole during G. mellonella infection with C. krusei or C. albicans. Effect of fluconazole during infection of larvae
with 56106 cells of C. krusei (ATCC 6258) per larvae (A and B) and 56105 cells of C. albicans cells (SC5314) per larva (C and D) in G. mellonella.
Fluconazole treatment with 4 or 12 mg/kg (A and C); 32, 64 or 128 mg/kg (B and D).
doi:10.1371/journal.pone.0060047.g005
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Figure 6. Efficacy of voriconazole, amphotericin B or caspofungin during C. krusei and C. albicans infection in G. mellonella. A and B)
Voriconazole treatment efficacy (7 and 10 mg/kg) in G. mellonella infected with C. albicans SC5314 (A) or C. krusei ATCC 6258 (B). C and D)
Amphotericin B treatment efficacy (1, 2, 4 mg/kg) in G. mellonella infected with C. albicans SC5314 (C) or C. krusei ATCC 6258 (D). E and F)
Caspofungin treatment efficacy (1, 2, 4 mg/kg) in G. mellonella infected with C. albicans SC5314 (E) or Candida krusei ATCC 6258 (F). In all the cases,
the larvae were infected with 56105 C. albicans cells/larva and 56106 C. krusei cells/larva.
doi:10.1371/journal.pone.0060047.g006
Figure 7. Effect of antifungal treatment on fungal burden in G. mellonella infected with C. albicans or C. krusei. Galleria mellonella larvae
were infected with C. krusei ATCC 6258 (A, 56106 cells/larva) or C. albicans SC5314 (B, 56105 cells/larva) and CFUs recovered from G. mellonella. Black
bars, no treatment, white bars, fluconazole (12 mg/kg), grey bars, amphotericin B (4 mg/kg).
doi:10.1371/journal.pone.0060047.g007
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evaluation of survival at different temperatures. The virulence of
five C. albicans strains with mutations in genes related to
filamentation was evaluated in G. mellonella and it was demon-
strated that this model is useful as a filamentation assay [53]. In the
case of C. neoformans, the virulence of different isolates, morpho-
genesis and antifungal treatments in G. mellonella showed good
Figure 8. Histopathology of G. mellonella infected with C. krusei and C. albicans and treated with different antifungals. Galleria
mellonella was infected with 56105 cells/larva of C. albicans SC5314 (C–H), or with 56106 cells/larva of C. krusei ATCC 6258 (K–P). After 96 hours of
infection, larvae were processed for histopathology as described in Material and Methods. (A, B, I, J), uninfected controls; (C, D, K and L), untreated
controls; (E, F, M and N), larvae treated with fluconazole (12 mg/kg); (G, H, O and P), larvae treated with amphotericin B (4 mg/kg). (A, C, E, G, I, K,
M, O), low magnification; (B, D, F, H, J, L, N and P), high magnification.
doi:10.1371/journal.pone.0060047.g008
Figure 9. Effect of antifungal treatment of haemocyte density and melanization of G. mellonella infected with C. krusei or C. albicans.
(A) Hemocytic density of G. mellonella infected with C. albicans SC5314 or C. krusei ATCC 6258 treated with amphotericin B (4 mg/kg) or fluconazole
(64 mg/kg). (B) Optical Density (OD) of the haemolymph of G. mellonella infected with C. albicans or C. krusei treated with amphotericin B (4 mg/kg)
or with fluconazole (64 mg/kg). Black bars, no treatment; grey bars, fluconazole; white bars, amphotericin B. * p,0.05.
doi:10.1371/journal.pone.0060047.g009
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correlation with mammalian system [57,58]. Previous work
demonstrated that C. elegans is susceptible to different Candida
species. For that reason, this host has been used to look for new
compounds with antifungal activity [44,46]. Besides, the available
C. elegans mutant animals defective in signaling pathways involved
in the immune system allows the study of the molecular
mechanisms of host-pathogen interaction [59]. However, there
are also some cases in which there is no correlation between
virulence in mammals and G. mellonella [60], so further studies are
required to validate the use of these models.
For these reasons, C. krusei offers a good model to validate the
use of invertebrate models. This yeast shows reduced virulence in
mammalian systems and fungal burden is significantly lower in
animals infected with C. krusei than in animals infected with other
fungal pathogens, such as C. albicans [61], so it is possible to
compare its virulence with other highly virulent yeasts. Moreover,
C. krusei is intrinsically resistant to fluconazole, so it offers an
excellent model to correlate antifungal efficacy in vitro and in vivo.
Previous work showed that G. mellonella infected with 26106
cells/larva of C. krusei killed 20% of the larvae after 72 hrs [62]. In
our work, we have reproduced the model and observed that larvae
killing can be faster by increasing the pathogen concentration.
However, C. krusei was less virulent than C. albicans because the
amount of yeast required to cause 100% death on the fourth day
was 10 times higher. This is also in agreement with the reduced
virulence of C. krusei in mammalian models [63,64], but also
indicates that G. mellonella offers a simple method to study virulence
traits of C. krusei. This finding is of particular interest, since not
every microorganism (i.e., Pneumocystis murina) can cause disease in
G. mellonella [65].
The possibility to incubate G. mellonella at different temperatures
is one of the best advantages of this model because it permits to
study virulence at both environment and mammalian tempera-
tures. The virulence of some pathogenic microorganisms (such as
Cryptococcus neoformans, Fusarium spp and Acinetobacter baumannii) in G.
mellonella is affected by the incubation temperature of the larvae
Figure 10. Virulence of C. krusei and C. albicans in C. elegans and antifungal efficacy. Caenorhabditis elegans was infected as described in
material and methods with C. krusei (ATCC 6258), C. albicans (SC5314) and E. coli OP50. (A) Visual appearance of infected worms (506magnification).
(B) Antifungal efficacy in C. elegans infected with C. albicans. ¤ OP50, N C. albicans, & C. albicans and treated with 2 mg/mL amphotericin B
(p,0.0001), m Fluconazole 12 mg/mL (p,0.0001); .Caspofungin 2 mg/mL (p,0.0001). (C) Antifungal efficacy during C. krusei infection ¤ OP50;N C.
krusei; & C. krusei treated with amphotericin B 2 mg/mL; (p,0.0001); mFluconazole 12 mg/mL (p = 0.1207); .Caspofungin 2 mg/mL (p,0.0001). (D)
Effect of voriconazole on survival of C. elegans worms infected with C. albicans (N, C. albicans, m, voriconazole 0.25 mg/L (p,0.0001); &,
voriconazole, 7.5 mg/L (p,0.0001); . voriconazole 10 mg/L (p,0.0001)). (E), Efficacy of voriconazole during infection of C. elegans by C. krusei (NC.
krusei; mvoriconazole 0.25 mg/L (p = 0.1217); . voriconazole 7.5 mg/L (9,0.0001); & voriconazole 10 mg/L (p,0.0001)).
doi:10.1371/journal.pone.0060047.g010
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after inoculation [66,67]. In contrast, no statistical difference in the
virulence of C. krusei was observed between the two temperatures.
This correlates with the growth rate of C. krusei at both
temperatures. In contrast to C. albicans, C. krusei growth was less
affected by the temperature. Interestingly, G. mellonella seems to
better tolerate environmental temperature than physiological
temperature, and it would be expected that immunity is impaired
at high temperature. However, our data indicate that in the case of
fungi with reduced virulence, immunity at high temperature can
control infection, and virulence of the fungus is more dependent
on virulence traits of the yeast. Candida krusei and C. albicans
produced filaments in G. mellonella, although the morphology was
different. Candida krusei tended to form cell aggregates with
melanization, characteristic of encapsulation. This result indicates
that G. mellonella differentially recognizes pathogenic yeasts, which
can be related to the different virulence exhibited by these two
Candida species.
Decrease in the amount of haemocytes has been associated with
increased susceptibility to fungal infections [39]. Candida krusei
induced a reduction in the proportion of haemocytes in a similar
way as C. albicans. This result suggests a mechanism of
phagocytosis avoidance by which Candida species induce killing
of G. mellonella, but does not explain the difference in virulence
shown by the different Candida spp. This reduction might be a
consequence of haemocyte explosion after filamentation of these
yeasts after internalization. Interestingly, Cryptococcus neoformans
does not cause a reduction in the number of hemocytes in the first
two hours post-infection [58,66], which might correlate with the
fact that this fungus is an intracellular pathogen and can survive in
phagocytic cells without affecting their viability [68,69]. In
addition, haemocytes are recruited at infection sites to form
clumps or nodules [38,70], so it is also possible that a proportion of
the haemocytes migrate from the haemolymph to the infection
sites. In agreement with our findings, it has been described that C.
albicans induced a reduction in the concentration of haemocytes. In
contrast, larvae infected with S. cerevisiae showed higher survival
and haemocytic concentration [39]. Moreover, the compound
[Ag2 (mal) (phen3)] increased the survival of larvae infected with
C. albicans, and also increased the haemocytic concentration [71].
Phagocytosis of C. krusei and C. albicans was also lower compared to
other fungi, such as C. neoformans. There are several mechanisms
that could account for this phenomenon. Candida spp might be
poorly phagocytosed due to impaired pathogen recognition by
insect haemocytes. In addition to the reduction of haemocyte
density and haemocyte explosion after filament formation
discussed above could also explain the reduced phagocytosis
observed. The future development of in vitro models to study yeast-
haemocyte interaction will be of great help to fully characterize
these phenomena.
Melanization is a humoral response of the insect that is
catalyzed by the enzyme phenoloxidase, and the reaction occurs
through the formation of capsules that surround foreign particles
[72]. We observed a fast melanization process after infection with
C. krusei. The degree of melanization depended on the inoculum
concentration, but not on the viability of the cells, indicating that
melanization is an unspecific process that depends on the presence
of foreign particles.
One of the main findings of our work is the correlation between
the in vivo efficacy of antifungals during C. albicans and C. krusei
infection and their in vitro susceptibility profiles. Fluconazole did
not have any protective effect during C. krusei infection in both G.
mellonella and C. elegans models. Similar findings have been
obtained with protection in immunosuppressed mice [63,73],
which validates the use of non-mammalian models to study
antifungal efficacy. Due to the simplicity of these models, we
believe that these hosts offer suitable and reliable systems to
evaluate antifungal efficacy in vivo. In this sense, C. elegans has been
successfully used to perform high-throughput assays to evaluate
fungal susceptibility to different types of compounds [46,74–76].
However, more information with resistant strains is required to
fully validate their use. We also noticed differences in the
protection between C. albicans and C. krusei in vivo after treatment
with voriconazole, amphotericin B and caspofungin. During C.
krusei infection, the caspofungin and amphotericin B concentra-
tions required for protection were always higher than during C.
albicans infection. Although C. krusei is considered susceptible to the
three drugs, it has reduced susceptibility to caspofungin and
amphotericin B compared to C. albicans [20,77,78]. So our data
are again in agreement with the different susceptibility profile
shown by these species in vitro. While several articles suggest
molecular mechanisms for the resistance to fluconazole exhibited
by C. krusei, it is not known why this species is less susceptible to
amphotericin B and caspofungin than C. albicans. The survival
experiments correlated with the fungal burden observed in the
larvae. Reduction of the fungal burden was very significant during
C. albicans with all the antifungals. In contrast, in larvae infected
with C. krusei, fluconazole had no effect on CFUs and the effect of
amphotericin B was less pronounced than in larvae inoculated
with C. albicans. These data indicate that larvae response is less
dynamic during C. krusei infection, which poses a limitation to
perform pharmacodynamic studies in this infection model. Similar
findings have been found in mammalian models. In immunosup-
pressed mice, fluconazole does not protect during C. krusei
infection and amphotericin B had a partial effect, while
anidulafungin treatment resulted in almost full survival of the
animals [79]. In agreement, in another study, fluconazole had a
very moderate effect in reducing fungal burden in neutropenic
mice compared to other azoles, such as isavuconazole [64]. The
use of antifungal combinations has not been sufficiently explored
to study the pharmacodynamics response during C. krusei infection,
and we believe that non mammalian models might offer a simple
and easy procedure to evaluate this important issue.
Caenorhabditis elegans is also useful to test antifungal efficacy
against several pathogenic fungi, including Candida spp and
Fusarium spp [44,80]. We found very similar results with C. elegans,
and these results are comparable with the ones found in G.
mellonella. This finding is important in the context of our work,
because we have been able to reproduce very similar results using
two different and independent host models. Despite the differences
in the immune responses between nematodes and insects, C. krusei
and C. albicans were virulent in both hosts. These results strongly
support the use of these hosts as screening models. Interestingly,
we could not find significant differences in the virulence of these
species in C. elegans, in contrast to the results found in G. mellonella,
where C. albicans was more virulent than C. krusei. We believe that
this difference between the behavior of the different yeast species
in G. melonella and C. elegans is the temperature at which the
virulence experiments are performed, which is significantly lower
in C. elegans.
Understanding fungal pathogenesis and the antifungal discovery
are key aspects in medical mycology. Non-conventional models
represent an important alternative for in vivo studies, even in the
case of organisms that present low virulence in mammalian
systems, such as C. krusei. Our results also demonstrate the
feasibility of non-mammalian models to identify new antifungal
compounds against resistant species. The correlation of the
virulence of pathogenic fungi in mammals and non-mammalian
models is still unclear. However, there is increasing evidence that
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some virulence phenotypes are reproduced in invertebrate models.
For this reason, we believe that more studies to validate the full use
of these hosts are required in the future.
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